Paul Robinson, director of CRU Group, gives tips for investors and comments on whether there’s anything that could derail hot commodities cobalt, zinc and copper.
Rick Rule discusses PDAC and gives his thoughts on a variety of metals, including hot commodities lithium and cobalt.
MGX Minerals (CSE:XMG) Chairman and CEO of U.S. subsidiary Petrolithium Corporation of America outlines the reasons he sees MGX founder Jared Lazerson as a visionary, and why he thinks MGX is the “first mover” in the Petro lithium space.
He believes the uranium market has bottomed.
Check Point® Software Technologies Ltd. (NASDAQ:CHKP), today announced its financial results for the fourth quarter and full year ended December 31, 2016.
Fourth Quarter 2016:Total Revenue: $487 million, a 6 percent increase year over yearSoftware Blades Subscriptions Revenues: $110 million, a 26 percent increase year over yearGAAP Operating Income: $241 million,
By Nick Smith
Sprott US Holdings’ President and CEO, Rick Rule talks about the junior resource sector in 2016 and the year ahead, particularly on precious metals, copper, lithium and uranium.
Cannabis stock analyst Alan Brochstein for his thoughts on the Bill Blair report to prime minister Justin Trudeau expected this month, sector catalysts and the recent stock rally in the US Marijuana stocks.
By Pia Rivera
Analyst, author and speaker David Morgan tells us about the impact of the US Elections on the price of gold and silver, and what’s in store for investors in 2017.
SpectraScience, a medical device company utilizing light technologies to detect and diagnose cancers, announced today that Dr. Noor Mohammed of Leeds University, Leeds England, presented clinical findings of the WavSTAT4 Optical Biopsy System.
On October 27, 2016, biotech experts and industry professionals will converge on London to discuss the sector’s outlook.
Newron Pharmaceuticals, a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central nervous system and pain, and its partners announced today that the FDA considers the September 2016 re-submission of the NDA by Newron to be a complete, Class 2 response to FDA’s
Celgene announced today that adult patients in England and Wales with chronic plaque psoriasis will now have access to oral OTEZLA®(apremilast) following a positive final appraisal determination from the National Institute for Health and Care Excellence.
Newron Pharmaceuticals, a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central nervous system and pain, and its partners Zambon S.p.A. and US WorldMeds, LLC, announced today that Newron has re-submitted the New Drug Application (NDA) for Xadago® (safinamide) to the US Food